Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 15, 2024 13:15 ET | Source: Spherix Global Insights

Hope on the Horizon: Nephrologists Emphasize Need for Innovative C3G Treatments as Novartis and Apellis Prepare Therapies for FDA Submission

EXTON, PA, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Complement 3 glomerulopathy (C3G) is a rare, progressive kidney disease characterized by inflammation and kidney damage. Patients with C3G often...
October 26, 2024 07:01 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024

Travere presents data on FILSPARI (sparsentan) in IgAN and FSGS at ASN Kidney Week 2024.
October 15, 2024 08:30 ET | Source: SeaStar Medical Holding Corporation

SeaStar Medical to Showcase New Mechanistic Data Highlighting the Immunomodulatory Effect of the Selective Cytopheretic Device in Acute Kidney Injury at ASN Kidney Week

DENVER, Oct. 15, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
October 14, 2024 16:30 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024

Travere Therapeutics will present 11 abstracts, including one late-breaking abstract, at the upcoming ASN Kidney Week 2024 in San Diego.
November 03, 2023 10:46 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023

“The totality of data from the PROTECT study demonstrates FILSPARI is effective, safe and has an important place in the IgAN treatment landscape ..."
October 13, 2023 16:30 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgAN and Phase 3 DUPLEX Study of sparsentan in FSGS 11 total abstracts accepted for...
November 02, 2021 16:30 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics to Present Abstracts at American Society of Nephrology Kidney Week 2021

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present abstracts based on non-clinical data...
October 19, 2020 09:00 ET | Source: Rénibus Therapeutics Inc.

Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2020

DALLAS, Texas, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that it will present five abstracts at the American Society of...